doi:10.3969/j.issn.1004-583X.2025.09.014

Abstract

CLC Number:

R733.4

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.09.014

https://www.lchc.cn/EN/Y2025/V40/I9/855

Figures/Tables 2

References 36

[1]	Sehn LH, Salles G. Diffuse large B-cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858.doi: 10.1056/NEJMra2027612.
[2]	Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study[J]. Blood, 2017, 130(16): 1800-1808.doi:10.1182/blood-2017-03-769620. pmid: 28774879
[3]	Siddiqi T. CARs vs bispecifics: The race is on![J]. Blood, 2024, 144(6): 592-593. doi: 10.1182/blood.2024025130. pmid: 39115828
[4]	李青, 邓琦. 嵌合抗原受体T细胞治疗复发难治弥漫大B细胞淋巴瘤进展[J]. 临床荟萃, 2022, 37(2): 182-187.doi:3969/j.issn.1004-583X.2022.02.018.
[5]	Ahmed G, Furqan F, Nasrollahi E, et al. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma[J]. Expert Rev Anticancer Ther, 2024, 24(8): 705-715.doi:10.1080/14737140.
[6]	Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: Opportunities and challenges[J]. Nat Rev Clin Oncol, 2024, 21(7): 539-560.doi:10.1038/s41571-024-00905-y.
[7]	Doraiswamy A, Shah MR, Bannerji R. Immunotherapies old and new: Hematopoietic stem cell transplant, chimeric antigen receptor T cells, and bispecific antibodies for the treatment of relapsed/refractory diffuse large B cell lymphoma[J]. Curr Hematol Malig Rep, 2021, 16(1): 72-81.doi: 10.1007/s11899-021-00610-y.
[8]	Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma[J]. Haematologica, 2025, 110(7): 1483-1499..doi:10.3324/haematol.2024.285343.
[9]	Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities[J]. Blood, 2023, 141(5): 467-480.doi:10.1182/blood.2021011994.
[10]	van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment[J]. Blood Cancer J, 2021, 11(2): 38.doi: 10.1038/s41408-021-00430-6.
[11]	Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study[J]. Lancet, 2021, 398(10306): 1157-1169.doi:10.1016/S0140-6736(21)00889-8. pmid: 34508654
[12]	Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2023, 41(12): 2238-2247.doi: 10.1200/JCO.22.01725.
[13]	Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody[J]. Leuk Lymphoma, 2021, 62(13): 3098-3108.doi: 10.1080/10428194.
[14]	Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2022, 387(24): 2220-2231.doi: 10.1056/NEJMoa2206913.
[15]	Birtas Atesoglu E, Gulbas Z, Uzay A, et al. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data[J]. Hematol Oncol, 2023, 41(4): 663-673..doi: 10.1002/hon.3174.
[16]	中国临床肿瘤学会淋巴瘤专家委员会. 格菲妥单抗治疗弥漫大B细胞淋巴瘤临床用药指导原则(2024年版)[J]. 白血病·淋巴瘤, 2024, 33(5): 257-264.doi: 10.3760/cma.j.cn115356-20240205-00020.
[17]	Kang C. Mosunetuzumab: First approval[J]. Drugs, 2022, 82(11): 1229-1234.doi: 10.1007/s40265-022-01713-3. pmid: 35947358
[18]	Bartlett NL, Assouline S, Giri P, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma[J]. Blood Adv, 2023, 7(17): 4926-4935.doi: 10.1182/bloodadvances.2022009260. pmid: 37067952
[19]	Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma[J]. Blood, 2016, 127(11): 1410-1416.doi: 10.1182/blood-2015-06-651380. pmid: 26755709
[20]	Hou JZ, Jacobs R, Cho SG, et al. Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) B-NHL[J]. Blood, 2022, 140(Supplement 1): 1474-1475.doi:10.1182/blood-2022-166385.
[21]	Patel K, Riedell PA, Tilly H, et al. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-hodgkin's lymphoma: Recommended dose safety/efficacy update and escalation exposure-response analysis[J]. Blood, 2022, 140(Supplement 1): 9470-9472.doi:10.1182/blood-2022-159586.
[22]	Budde E, Gopal AK, Flinn IW, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136(Supplement 1): 45-46.doi:10.1182/blood-2020-134983.
[23]	Song Y, Li Z, Li L, et al. GB261, an Fc-function enabled and CD3 affinity de-tuned CD20/CD3 bispecific antibody, demonstrated a highly advantageous safety/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed/refractory non-Hodgkin lymphoma[J]. Blood, 2023, 142(Supplement 1): 1719-1719.doi:10.1182/blood-2023-188444.
[24]	Lu H, Oka A, Coulson M, et al. PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies[J]. Blood, 2022, 140(Supplement 1): 3148-3148.doi:10.1182/blood-2022-168904.
[25]	Meetze K, Mehta NK, Li B, et al. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression[J]. J Immunother Cancer, 2023, 11(8):e007398. doi: 10.1136/jitc-2023-007398.
[26]	Piccione EC, Juarez S, Liu J, et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells[J]. MAbs, 2015, 7(5): 946-956.doi: 10.1080/19420862.2015.1062192. pmid: 26083076
[27]	Zhu D, Hadjivassiliou H, Jennings C, et al. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional Fc, selectively targets and depletes non-Hodgkin's lymphoma[J]. MAbs, 2024, 16(1): 2310248.doi: 10.1080/19420862.2024.2310248.
[28]	Cassanello G, Luna de Abia A, Falchi L. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma[J]. Oncoimmunology, 2024, 13(1): 2321648.doi: 10.1080/2162402X.2024.2321648.
[29]	Kim J, Cho J, Lee MH, et al. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis[J]. Blood, 2024, 144(6): 629-638. doi: 10.1182/blood.2023023419.
[30]	Brooks TR, Caimi PF. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma[J]. Blood Rev, 2024, 63: 101140.doi: 10.1016/j.blre.2023.101140.
[31]	Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas[J]. Blood Cancer J, 2024, 14(1): 27.doi: 10.1038/s41408-024-00997-w.
[32]	Herrera M, Pretelli G, Desai J, et al. Bispecific antibodies: advancing precision oncology[J]. Trends Cancer, 2024, 10(10): 893-919.doi: 10.1016/j.trecan.2024.07.002.
[33]	Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma[J]. Hematology Am Soc Hematol Educ Program, 2023, 2023(1): 332-339.doi:10.1182/hematology.2023000433. pmid: 38066842
[34]	Wei J, Zheng H, Dai S, et al. A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023[J]. Heliyon, 2024, 10(2): e23929.doi: 10.1016/j.heliyon.2023.e23929.
[35]	Brody JD, Jørgensen J, Belada D, et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial[J]. Blood, 2025, 145(15): 1621-1631.doi: 10.1182/blood.2024026830.
[36]	Long M, Mims AS, Li Z. Factors affecting the cancer immunotherapeutic efficacy of T cell bispecific antibodies and strategies for improvement[J]. Immunol Invest, 2022, 51(8): 2176-2214. doi: 10.1080/08820139.2022.2131569.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 36

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Doudou, Jiang Jian, Zhao Wei, Li Xuerong, Sun Lirong, Wang Lingzhen. Castleman's disease of the abdomen in children: Report of two cases and literature review [J]. Clinical Focus, 2025, 40(7): 643-646.
[2]	Yang Wei, He Chendong. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with dry cough as the only symptom: A case and literature review [J]. Clinical Focus, 2023, 38(7): 623-627.
[3]	Lu Luo, Wang Fei, Gu Weiying. Clinical determination of lymphocyte subsets in peripheral blood of patients with angioimmunoblastic T cell lymphoma [J]. Clinical Focus, 2022, 37(11): 1001-1007.
[4]	. [J]. Clinical Focus, 2022, 37(2): 182-187.
[5]	Shen Rui, Lei Yanhua, Jia Haokun. Analysis of the incidence and risk factors for venous thromboembolism in 145 patients with diffuse large B-cell lymphoma [J]. Clinical Focus, 2022, 37(1): 43-45.
[6]	Zhao Weihua, Xu Haiping, Peng Zhigang, Yao Yibing, Jiang Yanfeng, Ma Jie. Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma [J]. Clinical Focus, 2016, 31(1): 59-62.
[7]	Du Jianwei;Wei Xudong. Current treatment of non Hodgkin lymphoma [J]. Clinical Focus, 2015, 30(10): 1110-1119.
[8]	Zhang Jiqing;Zhong Lei;Li Jine. Role of arsenic trioxide induced apoptosis in Burkitt lymphoma cell line Raji and influence on C-myc expression [J]. Clinical Focus, 2015, 30(10): 1123-1126.
[9]	. [J]. Clinical Focus, 2015, 30(6): 692-693.
[10]	LI Li-juan;GUO Xiao-jia;ZHANG Lian-sheng. Advances in treatment of diffuse large B-cell lymphoma [J]. Clinical Focus, 2014, 29(10): 1134-1139.
[11]	LIU Yao;ZHANG Xi. Treatment and advance in mantal cell lymphoma [J]. Clinical Focus, 2014, 29(10): 1140-1146.
[12]	HUANG Wen-qiu;WANG Yi-ni;WANG Zhao. Treatment advance in hemophagocyric lymphohistiocytosis [J]. Clinical Focus, 2014, 29(10): 1147-1150.
[13]	. @@ [J]. Clinical Focus, 2014, 29(10): 1191-1194.
[14]	LU Xiao-lin;ZHU Hai-yan;JING Yu;YU Li. Autologous stem cell transplantation for 2 patients with primary central nervous system lymphoma [J]. Clinical Focus, 2014, 29(6): 640-643.
[15]	WEI An-wei;YUE Ya-guang;CHEN Guang-xia;JIANG Kui;WANG Bang-mao;ZHOU Lu;XU Dong-bo. Significance of interleukin 17 and interleukin 8 in gastric mucosa-associated lymphoid tissue lymphoma [J]. CLINICAL FOCUS, 2013, 28(11): 1246-0.